Faeth Therapeutics, Inc. (FTH) stock
FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.04−0.24 (-2.59%)
Close on Nov 17, 2026Market cap $233.60MP/E –Yield –
Faeth Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Faeth Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$198.82M. For fiscal 2025 it was -$22.29M. The highest annual figure on record is -$19.45M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.29M | – |
| FY2024 | Dec 31, 2024 | -$32.61M | – |
| FY2023 | Dec 31, 2023 | -$37.06M | – |
| FY2022 | Dec 31, 2022 | -$50.19M | – |
| FY2021 | Dec 31, 2021 | -$37.48M | – |
| FY2020 | Dec 31, 2020 | -$19.45M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$170.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.94M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.41M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.32M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.10M | – |
See a number that looks wrong?